SCHEMBL4487573

SCHEMBL4487573

COc1cc2nccc(Oc3ccc(Nc4ccc(C(C)(C)C)cc4)c(C)c3C)c2cc1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 17/20 1.00
PDGFRB P09619 1/20 0.55
KIT P10721 1/20 0.55
PDGFRA P16234 1/20 0.55
KDR P35968 1/20 0.55
EGFR P00533 1/20 0.52
GAK O14976 1/20 0.51
RIPK2 O43353 1/20 0.51
COQ8A Q8NI60 1/20 0.51
NLK Q9UBE8 1/20 0.51
MET P08581 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4464562 0.86 FGFR2 (0.84) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4473989 0.85 FGFR2 (0.76) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4465115 0.84 FGFR2 (1.00) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4471756 0.84 FGFR2 (0.85) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4472020 0.82 FGFR2 (1.00) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4477346 0.82 FGFR2 (0.77) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4461972 0.82 FGFR2 (1.00) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL5825569 0.82 FGFR2 (0.69) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4474144 0.82 FGFR2 (1.00) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4471414 0.82 FGFR2 (0.80) FGFR2PDGFRBKITPDGFRAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 FGFR2 2/4885PDGFRB 202/4885KIT 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.